MilliporeSigma says the extra fees, which will take effect Monday, are a direct response to President Donald Trump's tariffs. The company is owned by Merck KGaA, which is based in Germany.

UnitedHealth Group and Amedisys have found buyers for key divestitures aimed at getting their $3.3 billion merger over the ...

Amedisys (AMED) reported $594.78 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.1%. EPS of $1.25 for the same period compares to $1.03 a year ago.

BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March ...

(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as ...

(RTTNews) - Amedisys (AMED) announced earnings for its first quarter that increased from the same period last year and beat the Street estimates. The company's bottom line totaled $61.01 million ...

Amedisys shares have climbed 3% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $93.56, an increase of almost 3% in the last 12 months.

BATON ROUGE, La. (AP) — BATON ROUGE, La. (AP) — Amedisys Inc. (AMED) on Wednesday reported first-quarter earnings of $61 million. On a per-share basis, the Baton Rouge, Louisiana-based company ...

Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The stock has a market cap of $3.03 billion, a PE ratio of 36.68, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89.

Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a market cap of $3.01 billion, a P/E ratio of 36.41, a PEG ratio of 1.78 and a beta of 0.89.